New Horizons in Cancer Research: Delivering Cures Through Cancer Science
November 2-5, 2016
Shanghai Marriott Parkview Hotel
Shanghai, P.R. China

Conference Co-Chairpersons
José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, MA, USA

Wednesday, November 2
15:30-17:45 Welcome and Keynote Addresses
Grand Ballroom 2-4

Welcome
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, MA, USA

Genomic-driven clinical studies in breast cancer
José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY, USA

The cell cycle mitotic regulator Nlp in genomic instability and tumorigenesis
Qimin Zhan, Chinese Academy of Medical Sciences, Beijing, China

17:45-19:45 Opening Reception
Grand Ballroom 1 and Foyer.

Thursday, November 3
8:30-10:30 Session 1: Genomics, Targeted Therapies, and Clinical Applications
Grand Ballroom 2-4
Chairperson: Nikhil Wagle, Dana-Farber Cancer Institute, Boston, MA, USA

Precision medicine for metastatic breast cancer
Nikhil Wagle

Novel ways to target EGFR signaling in lung cancer
Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, TN, USA
How to design a clinical trial in GI cancer based on precision medicine
Rui-hua Xu, Sun Yat-sen University Cancer Center, Guangzhou, China

10:30-11:00
Tea Break
Grand Ballroom 1 and Grand Ballroom Foyer

11:00-13:00
Session 2: Epigenetic Mechanisms in Cancer Development and Therapy
Grand Ballroom 2-4
Chairperson:
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, MA, USA

Histone methylation regulation, recognition and link to human diseases
Yang Shi, Boston Children’s Hospital, Boston, MA, USA

Targeting epigenetic mechanisms in cancer
Scott A. Armstrong

Targeting non-coding RNA as a new paradigm in human glioma treatment
Yutaka Kondo, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

13:00-15:30
Poster Session A with Lunch
Ballroom 1-3
- Clinical Research and Clinical Trials
- Immunology
- Molecular Biology
- Tumor Biology

15:45-17:15
Professional Advancement Session: Getting Your Research Published
Grand Ballroom 2-4

Presenter: José Baselga, Editor-in-Chief, Cancer Discovery

Friday, November 4

8:15-9:15
Keynote Address
Grand Ballroom 2-4

MicroRNAs as key regulators of homeostasis
David Baltimore, California Institute of Technology, Pasadena, CA, USA

9:15-11:00
Session 3: Tumor Heterogeneity in Cancer Development and Progression
Grand Ballroom 2-4
Chairperson: Luis F. Parada, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Intratumor heterogeneity of genomic alterations and clonal evolution in esophageal squamous cell carcinoma
Ming-Rong Wang, Peking Union Medical College, Beijing, China

The role of cell of origin and cancer stem cells in GBM phenotype
Luis F. Parada

11:00-11:30
Tea Break
Grand Ballroom 1 and Grand Ballroom Foyer

11:30-13:30
Session 4: Tumor Metabolism and Developmental Pathways
Grand Ballroom 2-4
Chairperson: Bin Tean Teh, National Cancer Center, Singapore, Singapore

Hippo signaling in growth control and beyond
Duojia D.J. Pan, Howard Hughes Medical Institute, UT Southwestern Medical Center, Dallas, TX, USA

The role of metabolism in cancer cachexia
Bin Tean Teh

Targeted inhibition of IDHm in cancer: The path to developing a new approach to AML treatment
Katharine Yen, Agios Pharmaceuticals, Inc., Cambridge, MA, USA

13:30-16:00
Poster Session B with Lunch
Ballroom 1-3
Bioinformatics and Computational Biology
Cellular Biology
Chemistry
Epidemiology
Experimental Molecular Therapy
Prevention Research
Tumor Biology

16:00-18:00
Session 5: Immunotherapy: Targeting Immune Mechanisms
Grand Ballroom 2-4
Chairperson: Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY, USA

From the clinic to the lab: Investigating immune responses to immune checkpoint therapies
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

CAR therapy beyond the CD19 paradigm
Michel Sadelain

Exploiting the functional interplay between the epigenome and host immune system to devise new cancer therapies
Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, VIC, Australia
DAY 4 – Saturday, November 5

8:30-10:30  
Session 6: Molecular Tumor Prevention: Early Detection  
Grand Ballroom 2-4  
Chairperson: Hongyang Wang, Eastern Hepatobiliary Surgery Institute, Shanghai, China

Liquid biopsies and the early diagnosis of cancer  
Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

Serum miRNAs as predictive and preventive biomarker in hepatocellular carcinoma  
Hongyang Wang

Exploiting exosome biology in the diagnosis and treatment of pancreatic cancer  
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

10:30-11:00  
Tea Break  
Grand Ballroom 1 and Grand Ballroom Foyer

11:00-12:20  
Session 7: Novel Targeted Approaches to Cancer Therapy  
Grand Ballroom 2-4  
Chairperson: Jilong Yang, Tianjin Medical University Cancer Hospital & Institute, Tianjin, China

The evolution of cancer in response to targeted therapies  
Jeffrey A. Engelman, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

Targeted approaches to sarcoma: Translational medicine and precision medicine in the sequencing era  
Jilong Yang

12:20-12:40  
Closing Remarks and Departure  
Grand Ballroom 2-4